FIFTH AMENDMENT TO COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • November 1st, 2023 • Exelixis, Inc. • Biological products, (no disgnostic substances)
This FIFTH AMENDMENT TO THE COLLABORATION AND LICENSE AGREEMENT (the “Fifth Amendment”) is entered into as of August 24, 2023 (the “Fifth Amendment Effective Date”) by and between Exelixis, Inc., a Delaware company having an address at 1851 Harbor Bay Parkway, Alameda, CA 94502, USA (“Exelixis”) and Ipsen Pharma SAS, a French corporation having an address at 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France (“Licensee”). Exelixis and Licensee may be referred to herein individually as a “Party” or collectively as the “Parties”.
CONFIDENTIAL SEPARATION AGREEMENT AND RELEASE OF ALL CLAIMSConsulting Agreement • November 1st, 2023 • Exelixis, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
This Confidential Separation Agreement and Release of All Claims ("Agreement") is entered into by and between Exelixis, Inc. ("Exelixis") and Vicki L. Goodman, M.D. ("Dr. Goodman"). Dr. Goodman and Exelixis are referred to collectively herein as the Parties. This Agreement will become effective on the eighth (8th) calendar day after Dr. Goodman signs this Agreement, so long as it has been signed by the Parties and Dr. Goodman has not revoked the Agreement before that date ("Effective Date").
